KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Common Equity: 2017-2025

Historic Common Equity for Elanco Animal Health (ELAN) over the last 8 years, with Sep 2025 value amounting to $6.7 billion.

  • Elanco Animal Health's Common Equity rose 3.46% to $6.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 billion, marking a year-over-year increase of 3.46%. This contributed to the annual value of $6.1 billion for FY2024, which is 2.04% down from last year.
  • As of Q3 2025, Elanco Animal Health's Common Equity stood at $6.7 billion, which was down 0.38% from $6.8 billion recorded in Q2 2025.
  • Elanco Animal Health's 5-year Common Equity high stood at $8.0 billion for Q1 2021, and its period low was $5.9 billion during Q2 2024.
  • Moreover, its 3-year median value for Common Equity was $6.4 billion (2025), whereas its average is $6.5 billion.
  • Per our database at Business Quant, Elanco Animal Health's Common Equity grew by 20.21% in 2021 and then decreased by 19.92% in 2024.
  • Elanco Animal Health's Common Equity (Quarterly) stood at $7.5 billion in 2021, then declined by 2.92% to $7.3 billion in 2022, then decreased by 14.62% to $6.2 billion in 2023, then declined by 2.04% to $6.1 billion in 2024, then increased by 3.46% to $6.7 billion in 2025.
  • Its Common Equity stands at $6.7 billion for Q3 2025, versus $6.8 billion for Q2 2025 and $6.4 billion for Q1 2025.